Pollinosan Hayfever tablets

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Ammi visnagai d1 dilution; Aralia racemose d2 trituration; Cardiospermum halicacabum d2 trituration; Thryallis glauca d3 trituration; Larrea mexicana d2 trituration; Luffa operculata d6 trituration; Okoubaka aubrevillei d2 trituration

Available from:

A.Vogel Ireland Limited

INN (International Name):

Ammi visnagai d1 dilution; Aralia racemose d2 trituration; Cardiospermum halicacabum d2 trituration; Thryallis glauca d3 trituration; Larrea mexicana d2 trituration; Luffa operculata d6 trituration; Okoubaka aubrevillei d2 trituration

Dosage:

milligram(s)

Pharmaceutical form:

Tablet

Authorization status:

Marketed

Authorization date:

2019-05-31

Patient Information leaflet

A.Vogel Ireland
Pollinosan tablets
IE - Dublin
CTD Module 1
July 2022
___________________________________________________________________________________
PACKAGE LEAFLET
PIL2580.e04
Page 1 of 5
Pollinosan (2) HK Tabl
Art. no. 01314900
PACKAGE LEAFLET: INFORMATION FOR THE USER
POLLINOSAN
HAYFEVER TABLETS
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS PRODUCT
BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
Always use this product exactly as described in this leaflet or as
your doctor,
pharmacist or nurse has told you.
•
Keep this leaflet. You may need to read it again.
•
Ask your pharmacist if you need more information or advice.
•
If you get any side effects, talk to your doctor, pharmacist or nurse.
This
includes any possible side effects not listed in this leaflet. See
section 4.
•
You must talk to a doctor if you do not feel better or if you feel
worse
after 7 days,
WHAT IS IN THIS LEAFLET
1.
What Pollinosan is and what it is used for
2.
What you need to know before you take Pollinosan
3.
How to take Pollinosan
4.
Possible side effects
5.
How to store Pollinosan
6.
Contents of the pack and other information
1.
WHAT POLLINOSAN IS AND WHAT IT IS USED FOR
Pollinosan is a homeopathic medicinal product containing the extracts
of
_Ammi visnaga_, _Aralia racemosa_, _Cardiospermum halicacabum_,
_Galphimia _
_glauca_, _Larrea mexicana_, _Luffa operculata_ and _Okoubaka
aubrevillei_.
It is used within the homeopathic tradition to relieve the symptoms
of:
•
Hayfever
•
Other forms of allergic rhinitis
Pollinosan is for use in adults and adolescents over 12 years.
Hayfever and allergic rhinitis are conditions where the body’s
immune system
reacts abnormally to external irritants (allergens) such as pollen,
animal
dander (material shed from the body of animals) and dust. Symptoms can
include sneezing, blocked nose, runny and itchy nose, itchy eyes and
throat.
A.Vogel Ireland
Pollinosan tablets
IE - Dublin
CTD Module 1
July 2022
_________________________________________________________________

Summary of Product characteristics

Health Products Regulatory Authority
21 September 2023
CRN00DV3M
Page 1 of 3
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Pollinosan Hayfever tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet (250 mg) contains:
_Ammi visnaga _1x
_Aralia racemosa _2x
_Cardiospermum halicacabum _2x
_Galphimia glauca _3x
_Larrea mexicana _2x
_Luffa operculata _6x
_Okoubaka aubrevillei _2x
Excipients with known effect:
Contains lactose monohydrate
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
Slightly yellowish, biconvex tablet with a triangular stamp.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
A homoeopathic medicinal product used within the homeopathic tradition
to relieve the symptoms of hayfever and other
forms of allergic rhinitis.
This product is indicated for use in adults and adolescents over 12
years.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
Adults, older people and adolescents over 12 years: Take 2 tablets 3
times daily before meals.
Maximum recommended daily dose is 6 tablets.
This product should not be used in children under 12 years.
METHOD OF ADMINISTRATION
For oral use only.
4.3 CONTRAINDICATIONS
Hypersensitivity to any of the active substances or to any of the
excipients listed in section 6.1.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Do not exceed the stated dose.
If the condition worsens or if symptoms persist for more than 7 days,
a qualified healthcare professional e.g. a doctor or
pharmacist should be consulted.
This product contains lactose. Patients with rare hereditary problems
of galactose intolerance, the Lapp lactose deficiency or
glucose-galactose malabsorption should not take this medicine.
This product is not recommended for use in children under 12 years of
age due to a lack of data on safety.
Health Products Regulatory Authority
21 September 2023
CRN00DV3M
Page 2 of 3
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
No interaction studies have been performed.
4.6 FERTILITY, PREGNANCY AND